{"entity":{"id":"nct06336291","kind":"trial","name":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","aka":[],"tldr":"A phase 2 trial of L19TNF in glioma & glioblastoma, run by Philogen S.p.A., active and no longer recruiting.","summary":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence is a phase 2 interventional study registered as NCT06336291 by Philogen S.p.A., with 90 participants enrolled, started 2024-05-22 and due to reach its primary completion in 2026-06. Interventions recorded: L19TNF and Lomustine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06336291","url":"https://clinicaltrials.gov/study/NCT06336291"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["philogen-s-p-a"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06336291","phase":"2","setting":"A Dose Optimization Study for L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","sponsor":"Philogen S.p.A.","enrolled":90,"outcomes":[]},"route":"/trials/nct06336291/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/"}]}}